Rational and results of weekly treatment with calcidiol in postmenopausal and senile osteoporosis
Abstract
Vitamin D plays a crucial role for the prevention and treatment of both postmenopausal and senile osteoporosis and possibly for a number of other conditions. The prevalence of vitamin D deficiency remains extremely high among elderly subjects. This indicates that both the perception of the problem and the interventions so far implemented remain inadequate. This is further complicated by the observation that the lower normal range of 25-hydroxycholecalciferol (calcidiol) and the minimum daily allowance of vitamin D have been recently set to values considerably higher. The association of calcidiol with the specific osteoporosis treatment, for example associating the two therapies on one specific day (once weekly) is an efficient way for increasing compliance and effectiveness of the osteoporosis therapy. The weekly dose of calcidiol may be adapted to individual needs, i.e 4,000 to 6,000 IU (or 20-30 drops) according to age or risk factors for vitamin D deficiency.
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.